Compare Mesoblast Limited (MESO) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Western Alliance Bancorporation — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while Western Alliance Bancorporation trades at $79.68 (market cap $8.84B). The key difference: Western Alliance Bancorporation is far larger — about 4.1× Mesoblast Limited's market cap, and Western Alliance Bancorporation pays a 2.07% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | WAL | |
|---|---|---|
Market Cap | $2.17B | $8.84B |
Sector | Technology | Financials |
52-Week High | $20.96 | $96.08 |
52-Week Low | $12.88 | $66.70 |
Enterprise Value | $2.17B | — |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Western Alliance Bancorporation (WAL) trades at $80.97, down 1.62% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company has consistently beaten earnings estimates in recent quarters, with a Q2 2026 EPS estimate of $2.33. Strong profitability is evident with a net income margin of 25.63% and ROE of 13.47%, while valuation ratios like a P/E of 9.58 suggest potential undervaluation. Recent news highlights operational achievements, including being named Arizona's #1 bank by Forbes in June 2026.
The outlook for WAL is positive, supported by analyst consensus with 79% buy ratings and a $90.67 price target, implying ~12% upside. Investment opportunities include earnings growth and sector leadership, but risks involve negative operating cash flow in 2025 and high interest expenses of $1.83B that could pressure margins if rates rise.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
